vs
ICF International, Inc.（ICFI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ICF International, Inc.的1.7倍（$772.1M vs $443.7M），Revvity净利率更高（12.7% vs 3.9%，领先8.8%），Revvity同比增速更快（5.9% vs -10.6%），Revvity自由现金流更多（$161.8M vs $68.7M），过去两年Revvity的营收复合增速更高（9.0% vs -5.3%）
ICF International是一家总部位于美国弗吉尼亚州雷斯顿的上市企业，主营咨询与技术服务，为各行业客户提供专业的解决方案支持，业务覆盖多领域的专业咨询及技术落地服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ICFI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$443.7M
营收增速更快
RVTY
高出16.5%
-10.6%
净利率更高
RVTY
高出8.8%
3.9%
自由现金流更多
RVTY
多$93.1M
$68.7M
两年增速更快
RVTY
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $443.7M | $772.1M |
| 净利润 | $17.3M | $98.4M |
| 毛利率 | 35.7% | — |
| 营业利润率 | 6.5% | 14.5% |
| 净利率 | 3.9% | 12.7% |
| 营收同比 | -10.6% | 5.9% |
| 净利润同比 | -29.5% | 3.9% |
| 每股收益（稀释后） | $0.95 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICFIRVTY
| Q4 25 | $443.7M | $772.1M | ||
| Q3 25 | $465.4M | $698.9M | ||
| Q2 25 | $476.2M | $720.3M | ||
| Q1 25 | $487.6M | $664.8M | ||
| Q4 24 | $496.3M | $729.4M | ||
| Q3 24 | $517.0M | $684.0M | ||
| Q2 24 | $512.0M | $691.7M | ||
| Q1 24 | $494.4M | $649.9M |
净利润ICFIRVTY
| Q4 25 | $17.3M | $98.4M | ||
| Q3 25 | $23.8M | $46.7M | ||
| Q2 25 | $23.7M | $53.9M | ||
| Q1 25 | $26.9M | $42.2M | ||
| Q4 24 | $24.6M | $94.6M | ||
| Q3 24 | $32.7M | $94.4M | ||
| Q2 24 | $25.6M | $55.4M | ||
| Q1 24 | $27.3M | $26.0M |
毛利率ICFIRVTY
| Q4 25 | 35.7% | — | ||
| Q3 25 | 37.6% | 53.6% | ||
| Q2 25 | 37.3% | 54.5% | ||
| Q1 25 | 38.0% | 56.5% | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 37.1% | 56.3% | ||
| Q2 24 | 35.7% | 55.7% | ||
| Q1 24 | 37.2% | 54.6% |
营业利润率ICFIRVTY
| Q4 25 | 6.5% | 14.5% | ||
| Q3 25 | 8.3% | 11.7% | ||
| Q2 25 | 8.4% | 12.6% | ||
| Q1 25 | 7.9% | 10.9% | ||
| Q4 24 | 7.3% | 16.3% | ||
| Q3 24 | 8.9% | 14.3% | ||
| Q2 24 | 8.3% | 12.4% | ||
| Q1 24 | 8.3% | 6.8% |
净利率ICFIRVTY
| Q4 25 | 3.9% | 12.7% | ||
| Q3 25 | 5.1% | 6.7% | ||
| Q2 25 | 5.0% | 7.5% | ||
| Q1 25 | 5.5% | 6.4% | ||
| Q4 24 | 4.9% | 13.0% | ||
| Q3 24 | 6.3% | 13.8% | ||
| Q2 24 | 5.0% | 8.0% | ||
| Q1 24 | 5.5% | 4.0% |
每股收益（稀释后）ICFIRVTY
| Q4 25 | $0.95 | $0.86 | ||
| Q3 25 | $1.28 | $0.40 | ||
| Q2 25 | $1.28 | $0.46 | ||
| Q1 25 | $1.44 | $0.35 | ||
| Q4 24 | $1.29 | $0.77 | ||
| Q3 24 | $1.73 | $0.77 | ||
| Q2 24 | $1.36 | $0.45 | ||
| Q1 24 | $1.44 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3M | $919.9M |
| 总债务越低越好 | $401.4M | — |
| 股东权益账面价值 | $1.0B | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.39× | — |
8季度趋势，按日历期对齐
现金及短期投资ICFIRVTY
| Q4 25 | $5.3M | $919.9M | ||
| Q3 25 | $4.0M | $931.4M | ||
| Q2 25 | $7.0M | $991.8M | ||
| Q1 25 | $5.7M | $1.1B | ||
| Q4 24 | $5.0M | $1.2B | ||
| Q3 24 | $6.9M | $1.2B | ||
| Q2 24 | $4.1M | $2.0B | ||
| Q1 24 | $3.7M | $1.7B |
总债务ICFIRVTY
| Q4 25 | $401.4M | — | ||
| Q3 25 | $449.4M | — | ||
| Q2 25 | $462.3M | — | ||
| Q1 25 | $502.0M | — | ||
| Q4 24 | $411.7M | — | ||
| Q3 24 | $419.1M | — | ||
| Q2 24 | $433.9M | — | ||
| Q1 24 | $474.7M | — |
股东权益ICFIRVTY
| Q4 25 | $1.0B | $7.3B | ||
| Q3 25 | $1.0B | $7.4B | ||
| Q2 25 | $1.0B | $7.6B | ||
| Q1 25 | $968.9M | $7.6B | ||
| Q4 24 | $982.5M | $7.7B | ||
| Q3 24 | $976.3M | $7.9B | ||
| Q2 24 | $943.3M | $7.9B | ||
| Q1 24 | $916.1M | $7.8B |
总资产ICFIRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.0B | $12.8B | ||
| Q2 24 | $2.0B | $13.4B | ||
| Q1 24 | $2.0B | $13.4B |
负债/权益比ICFIRVTY
| Q4 25 | 0.39× | — | ||
| Q3 25 | 0.44× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.42× | — | ||
| Q3 24 | 0.43× | — | ||
| Q2 24 | 0.46× | — | ||
| Q1 24 | 0.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $68.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 15.5% | 21.0% |
| 资本支出强度资本支出/营收 | 1.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 4.37× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $120.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ICFIRVTY
| Q4 25 | $75.6M | $182.0M | ||
| Q3 25 | $47.3M | $138.5M | ||
| Q2 25 | $52.0M | $134.3M | ||
| Q1 25 | $-33.0M | $128.2M | ||
| Q4 24 | $95.4M | $174.2M | ||
| Q3 24 | $25.5M | $147.9M | ||
| Q2 24 | $60.6M | $158.6M | ||
| Q1 24 | $-10.0M | $147.6M |
自由现金流ICFIRVTY
| Q4 25 | $68.7M | $161.8M | ||
| Q3 25 | $41.8M | $120.0M | ||
| Q2 25 | $46.2M | $115.5M | ||
| Q1 25 | $-36.5M | $112.2M | ||
| Q4 24 | $89.5M | $149.8M | ||
| Q3 24 | $20.4M | $125.6M | ||
| Q2 24 | $55.5M | $136.6M | ||
| Q1 24 | $-15.2M | $129.7M |
自由现金流率ICFIRVTY
| Q4 25 | 15.5% | 21.0% | ||
| Q3 25 | 9.0% | 17.2% | ||
| Q2 25 | 9.7% | 16.0% | ||
| Q1 25 | -7.5% | 16.9% | ||
| Q4 24 | 18.0% | 20.5% | ||
| Q3 24 | 3.9% | 18.4% | ||
| Q2 24 | 10.8% | 19.7% | ||
| Q1 24 | -3.1% | 20.0% |
资本支出强度ICFIRVTY
| Q4 25 | 1.6% | 2.6% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 0.7% | 2.4% | ||
| Q4 24 | 1.2% | 3.4% | ||
| Q3 24 | 1.0% | 3.3% | ||
| Q2 24 | 1.0% | 3.2% | ||
| Q1 24 | 1.1% | 2.7% |
现金转化率ICFIRVTY
| Q4 25 | 4.37× | 1.85× | ||
| Q3 25 | 1.99× | 2.97× | ||
| Q2 25 | 2.20× | 2.49× | ||
| Q1 25 | -1.23× | 3.03× | ||
| Q4 24 | 3.88× | 1.84× | ||
| Q3 24 | 0.78× | 1.57× | ||
| Q2 24 | 2.37× | 2.87× | ||
| Q1 24 | -0.37× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICFI
| US Federal Government | $166.7M | 38% |
| Commercial | $164.4M | 37% |
| US State And Local Government | $78.7M | 18% |
| International Government | $33.8M | 8% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
